[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-367204-105":59,"doc-detail-367204-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","therapeutic-vaccines-for-hematological-cancers-a-scoping-review-of-this-immunotherapeutic-approach-as-alternative-to-the-treatment-of-these-malignancies","Therapeutic Vaccines for Hematological Cancers - A Scoping Review of This Immunotherapeutic Approach as Alternative to the Treatment of These Malignancies","","Innovative cancer treatments increasingly rely on immunotherapy, and therapeutic vaccines are explored for their ability to mobilize immune cells to eliminate tumor cells. This scoping review systematically identifies and analyzes recent studies on therapeutic immunotherapy vaccines for hematological cancers, addressing development stages, therapeutic validation assays, treatment outcomes, and study limitations. The analysis synthesizes evidence from 2013–2024, highlighting most studies in preclinical phases, and emphasizing both progress and translation gaps between models and patients.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/therapeutic-vaccines-for-hematological-cancers-a-scoping-review-of-this-immunotherapeutic-approach-as-alternative-to-the-treatment-of-these-malignancies/367204/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/therapeutic-vaccines-for-hematological-cancers-a-scoping-review-of-this-immunotherapeutic-approach-as-alternative-to-the-treatment-of-these-malignancies/367204.png","ImageObject",300,407,{"name":92,"@type":93},"Asher","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main purpose of the scoping review?","Question",{"text":112,"@type":113},"To systematically identify and analyze recent studies on therapeutic immunotherapy vaccines for hematological cancers, focusing on development stages, validation assays, outcomes, and limitations.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How many studies were included, and what period do they cover?",{"text":117,"@type":113},"A total of 56 articles were included, published from 2013 to 2024.",{"name":119,"@type":110,"acceptedAnswer":120},"Which cancer type appears most frequently in the reviewed studies?",{"text":121,"@type":113},"Acute myeloid leukemia is reported as the most frequently studied malignancy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},367204,1792183586,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},687197207639,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Systematic Review  \nTherapeutic Vaccines for Hematological Cancers: A Scoping Review of This Immunotherapeutic Approach as Alternative to the Treatment of These Malignancies  \nFernando Augusto Siqueira Mathias 1, Maria Gabriela Reis Carvalho 1,2,* and Jeronimo Conceição Ruiz 1,2, *  \nAcademic Editors: Jenny Bulgarelli and Sara Pignatta  \nReceived: 6 November 2024  \nRevised: 17 January 2025  \nAccepted: 21 January 2025  \nPublished: 23 January 2025  \nCitation: Mathias, F.A.S.; Carvalho, M.G.R.; Ruiz, J.C. Therapeutic Vaccines for Hematological Cancers:  \nA Scoping Review of This Immunotherapeutic Approach as Alternative to the Treatment of These Malignancies. Vaccines 2025, 13, 114 . [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)vaccines13020114  \nCopyright: © 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://creativecommons.org/](https://creativecommons.org/)[ ](https://creativecommons.org/)[licenses/by/4.0/](licenses/by/4.0/)) .  \n1 Grupo de Informática de Biossistemas, Instituto René Rachou, Fundação Oswaldo Cruz, Belo Horizonte 30190-002, Brazil; [fasmathias@gmail.com](fasmathias@gmail.com)  \n2 Biologia Computacional e Sistemas (BCS), Instituto Oswaldo Cruz (IOC), Fundação Oswaldo Cruz, Rio de Janeiro 21040-900, Brazil  \n* Correspondence: maria.carvalho@fiocruz.br (M.G.R.C.); jeronimo.ruiz@fiocruz.br (J.C.R.)  \nAbstract: Background/Objectives: The need for innovative cancer treatments has brought immunotherapies to the forefront as a promising approach, with therapeutic vaccines demonstrating the potential to mobilize immune cells to eliminate tumor cells. However, challenges such as genetic variability among patients, immune evasion mechanisms, and disease relapse contribute to the complexity of achieving an ideal therapy, especially for hematological cancers. This review systematically identifies and analyzes recent studies focused on the development of therapeutic immunotherapy vaccines, examining critical aspects such as development stages, key assays for therapeutic validation, treatment outcomes, and study limitations. Methods: A scoping review was conducted following the PRISMA extension guidelines (PRISMA-ScR) . Literature searches were conducted across Scopus, PubMed, Web of Science, and Science Direct databases using keywords including “immunotherapy”,“vaccines”,“immunization”,“hematological malignancies”,“blood cancer”,“hematopoietic neoplasms”, and “leukemia”. Results: A total of 56 articles published from 2013 to 2024 were included in the analysis. The majority of studies are in the preclinical stage, with some advancing to phase 1 and phase 2 clinical trials. Acute myeloid leukemia emerged as the most frequently studied malignancy. While first-and secondgeneration vaccines dominate the field, innovative approaches, such as dendritic-cellbased vaccines and mRNA vaccines, are gaining prominence. Notably, preclinical models often demonstrate superior outcomes compared to clinical trials, as results observed in animal models are not fully replicated in human studies. Conclusions: Despite challenges related to disease progression and patient loss, the studies reviewed highlight significant advancements in patient prognosis, emphasizing the potential of novel therapeutic vaccines as an effective alternative for the treatment of hematological cancers.  \nKeywords: immunotherapy; vaccine; hematological cancers  \n1. Introduction  \nHematological cancers, encompassing various conditions such as leukemias, lymphomas, and myelomas, continue to pose complex challenges in the field of oncology. A study published in 2023, analyzing data on hematological malignancies from 1990 to 2019, highlighted that these cancers are among the most prevalent, with global incidence and mortality rates increasing over this period. Additionally, the age-standardize","cbCainS1weCaC6wq","https://ap.wps.com/l/cbCainS1weCaC6wq","pdf",1862763,39,"English","# Abstract\n# 1. Introduction\n## Hematological cancers and unmet clinical needs\n## Immunology background and current treatment limitations\n# Methods and outcomes overview\n## Literature search strategy\n## Included studies and study stages\n## Vaccine platforms and comparative findings\n# Conclusions","[{\"question\":\"What is the main purpose of the scoping review?\",\"answer\":\"To systematically identify and analyze recent studies on therapeutic immunotherapy vaccines for hematological cancers, focusing on development stages, validation assays, outcomes, and limitations.\"},{\"question\":\"How many studies were included, and what period do they cover?\",\"answer\":\"A total of 56 articles were included, published from 2013 to 2024.\"},{\"question\":\"Which cancer type appears most frequently in the reviewed studies?\",\"answer\":\"Acute myeloid leukemia is reported as the most frequently studied malignancy.\"}]","Therapeutic Vaccines for Hematological Cancers - A Scoping Review of This Immunotherapeutic Approach as Alternative to the Treatment of These Malignancies | PDF",1790169698,98,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6a428d70baeae2f4162ba02c76501a3.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/94c51e26837f4ae4709c0a1b7b1dd9a1.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c51b9c8360ac3510b4f9ce365f4b8d16.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f71599349de24a3a77d0cac08ca44732.webp",980,1385]